Solara Active Pharma Sciences Limited EBIT

Solara Active Pharma Sciences Limited's ebit stands at $910M as of June 2026. That compares with $1.3B in the prior-year period — down 31.3% year over year. That is below the sector sector average of $2.6T. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Solara Active Pharma Sciences Limited reported $910M in EBIT versus $1.3B a year earlier — a 31.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Solara Active Pharma Sciences Limited sits lower the its sector benchmark ($2.6T) with a EBIT of $910M. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $1.3B in the prior-year period — down 31.3% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Solara Active Pharma Sciences Limited's EBIT evolved across reporting periods, while the comparison chart places SOLARA.NS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.